TERACHEM 2026 Keynote Speakers
Dr. Ulli Köster
Dr. Ulli Köster is research scientist at Institut Laue-Langevin (ILL) since 2006 and associate professor at the Université Grenoble Alpes (Chair “Grands Instruments Européens”). ILL is an international research centre in Grenoble (France) that operates a high-flux reactor, supplying neutrons to over 40 scientific instruments. Ulli Köster is responsible for the fission fragment separator LOHENGRIN and coordinator of radionuclide production at ILL. He obtained a PhD in physics at TU Munich, was then CERN Fellow at the radioactive isotope separator ISOLDE (CERN) and coordinator of the EU project TARGISOL. He is currently work package leader for “Production and dispatch of non-conventional radioisotopes” in the EU project “PRISMAP – The European Medical Radionuclides Programme” and president of the scientific committee of ARRONAX Nantes.
Prof. Peter J. H. Scott
Prof. Peter J. H. Scott is the Paul L. Carson Collegiate Professor of Radiology at the University of Michigan, with courtesy appointments in Medicinal Chemistry and Pharmacology, Director of the PET Center and the Associate Chair for Research. Scott's group is involved in all aspects of Radiopharmaceutical Sciences including: i) developing new methods for producing radionuclides and radiolabeling bioactive molecules, ii) designing and translating new radiotracers for PET imaging, iii) cGMP radiopharmaceutical manufacture, and iv) adapting new technology (e.g. artificial intelligence) to imagine the radiochemistry laboratory of the future. Peter has published over 210 papers and 30 book chapters, about 270 conference abstracts and edited 5 books. He has received numerous awards for his research including, most recently, the 2023 Sam Gambhir Trailblazer Award from SNMMI, and is listed as an inventor on multiple patents. His laboratory is funded by the National Institutes of Health, and has multiple collaborations with academic institutions, biotech and pharma companies all over the world.
Dr. Michael K. Schultz
Dr. Michael K. Schultz is an accomplished scientist and NIH-funded investigator with tenure as Associate Professor of Radiology, Pediatrics, Free Radical and Radiation Biology, and Chemistry at the University of Iowa, Dr. Shultz is also the Founder and Chief Science Officer of Perspective Therapeutics, a pharmaceutical company specializing in radiopharmaceutical therapies for cancer.
Dr. Julie L. Sutcliffe
Dr. Sutcliffe is a Professor of Internal Medicine and Biomedical Engineering at the University of California Davis. She serves as the co-director of the Center for Molecular and Genomic imaging and as the director of radiochemistry. Dr. Sutcliffe’s laboratory focuses on the design, synthesis, invitro evaluation, and in vivo screening of targeted molecular imaging agents and therapeutics, with the goal of rapid deployment to the clinic. Dr. Sutcliffe is the Principal investigator of 5 active clinical trials and is the leader of the UC Davis Lustgarten Foundation/ StandupToCancer Pancreatic Cancer Collective Research Team. She is a Fellow of the Society of Nuclear Medicine and Molecular Imaging, a Fellow of the World Molecular Imaging Society and Fellow of the American Institute for Medical and Biological Engineering.